D. Boral Capital reaffirmed their buy rating on shares of VolitionRx (NYSE:VNRX – Free Report) in a report released on Wednesday morning,Benzinga reports. The brokerage currently has a $5.00 price objective on the stock.
Other equities analysts have also issued research reports about the company. Benchmark reissued a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd. StockNews.com assumed coverage on VolitionRx in a report on Wednesday. They issued a “sell” rating on the stock.
Check Out Our Latest Analysis on VolitionRx
VolitionRx Trading Down 3.6 %
Hedge Funds Weigh In On VolitionRx
Large investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in VolitionRx by 15.1% in the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after acquiring an additional 95,900 shares in the last quarter. Millennium Management LLC acquired a new position in VolitionRx in the fourth quarter valued at $36,000. Northern Trust Corp boosted its stake in VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares in the last quarter. Lagoda Investment Management L.P. boosted its stake in VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after acquiring an additional 1,481,000 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new position in VolitionRx in the fourth quarter valued at $29,000. Institutional investors and hedge funds own 8.09% of the company’s stock.
About VolitionRx
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Recommended Stories
- Five stocks we like better than VolitionRx
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- How Can Investors Benefit From After-Hours Trading
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- EV Stocks and How to Profit from Them
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.